Rybrevant combination extends PFS in EGFR-mutant non-small cell lung cancer
Click Here to Manage Email Alerts
Amivantamab plus lazertinib improved PFS compared with osimertinib as first-line therapy in adults with locally advanced or metastatic EGFR-mutated non-small cell lung cancer, according to the agent’s manufacturer.
OS data remained immature as of an interim analysis of results from the randomized phase 3 MARIPOSA trial.
The manufacturer reported no new safety signals associated with the use of amivantamab-vmjw (Rybrevant, Janssen) — an EGFR-/MET-directed bispecific antibody — or lazertinib (Leclaza; Yuhan, Janssen) and a safety profile similar to results seen in previous studies using the two agents in combination.
“Positive topline results from the MARIPOSA study reinforce the potential of the Rybrevant and lazertinib combination in front-line EGFR-mutated non-small cell lung cancer as a future standard of care,” Peter Lebowitz, MD, PhD, global therapeutic area head for oncology at Janssen Research & Development, said in a company-issued press release “As a combination targeted regimen, Rybrevant and lazertinib inhibit critical oncogenic driver pathways and activate the immune system to address disease in multiple ways.”
The open-label MARIPOSA trial enrolled 1,074 adults with newly diagnosed and untreated locally advanced or metastatic NSCLC with EGFR exon 19 deletions (ex19del) or substitution mutations.
Investigators randomly assigned study participants to receive amivantamab plus lazertinib, lazertinib plus osimertinib (Tagrisso, AstraZeneca), or osimertinib alone.
The trial met its primary endpoint by showing “statistically significant and clinically meaningful improvement” in PFS among study participants who received the combination of amivantamab plus lazertinib compared with osimertinib, the release stated.
The manufacturer said it plans to submit results for presentation at an upcoming major scientific meeting, including additional data on certain secondary study endpoints.
Click Here to Manage Email Alerts